TG Therapeutics, Inc.

TGTX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001001316

A

strongest fifth of 305 graded peers in healthcare

rank 50 of 305; percentile 16.1; sampling error 2.8 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	C/D percentile 61.7
Solvency	B/C percentile 37.5
Growth and financing	A percentile 11.5
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.1B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	7 of 13
Graded from	filings received through Feb 27, 2026 266 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$64.90 2026-11-19; market equity $9.8B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 61.7						
Gross profitability	48.5%	32.8%		25.2	346	2025-12-31
Return on invested capital	not computable	9.6%				

latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	57.5%	(6.7%)	98.3	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 3					
Solvency, sleeve percentile 37.5					
Altman Z double-prime	2.04	0.31	29.7	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Interest coverage	not computable	(3.61x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	4.10x	2.68x	45.3	781	2025-12-31
Growth and financing, sleeve percentile 11.5					
Revenue growth, three-year compound	504.9%	9.6%	0.3	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	76.4%	3.2%	4.4	663	2025-12-31
Net share issuance, one year	1.7%	1.6%	30.0	625	2026-02-25

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
45	PRO DEX Inc. (PDEX)	14.5	A	
46	Insulet Corp. (PODD)	14.8	A	
47	Ardelyx, Inc. (ARDX)	15.1	A	
48	Lantheus Holdings, Inc. (LNTH)	15.5	A	
49	Harrow, Inc. (HROW)	15.8	A	late filer
50	TG Therapeutics, Inc. (TGTX)	16.1	A	
51	Natures Sunshine Products Inc. (NATR)	16.4	A	fortress balance sheet
52	Alnylam Pharmaceuticals, Inc. (ALNY)	16.8	A	
53	Aurinia Pharmaceuticals Inc. (AUPH)	17.1	A	
54	Acadia Pharmaceuticals Inc. (ACAD)	17.4	A/B	
55	UFP Technologies Inc. (UFPT)	17.8	A/B	

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	60.4%	(1.7%)	83
Distance from 52-week high	(1.9%)	(31.7%)	97
EBIT to enterprise value	1.3%	0.5%	54
Free cash flow yield	(0.3%)	0.6%	45
Book value to price	0.06	0.29	18

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.06	0.37	13
Composite equity issuance, five years	7.2%	13.5%	41
Relative strength against the sector, log excess return	0.30	(0.19)	83
Twelve-month failure probability, CHS model	0.02%	0.06%	17

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$429.4M
Operating cash flow, four quarters	$86.3M
Months of runway	not finite
Days since last periodic filing	11 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$92.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$616.3M	2025-12-31	2026-02-27	10-K	26-006133
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$100.7M	2025-12-31	2026-02-27	10-K	26-006133
3	assets	us-gaap:Assets	$1.1B	2025-12-31	2026-02-27	10-K	26-006133
4	operating income	us-gaap:OperatingIncomeLoss	$20.6M	2023-12-31	2026-02-27	10-K	26-006133
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$13.1M	2023-12-31	2026-02-27	10-K	26-006133
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$390,000	2023-12-31	2026-02-27	10-K	26-006133
7	total debt	us-gaap:LongTermDebt	$100.4M	2023-12-31	2024-02-29	10-K	24-006144
8	book equity	us-gaap:StockholdersEquity	$160.5M	2023-12-31	2026-02-27	10-K	26-006133
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$92.9M	2023-12-31	2026-02-27	10-K	26-006133
10	total debt	us-gaap:LongTermDebt	$71.1M	2022-12-31	2023-03-01	10-K	23-002610
11	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	$58.6M	2022-12-31	2023-03-01	10-K	23-002610
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$102.3M	2022-12-31	2025-03-03	10-K	25-005908
13	net income	us-gaap:NetIncomeLoss	$447.2M	2025-12-31	2026-02-27	10-K	26-006133
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$24.8M	2025-12-31	2026-02-27	10-K	26-006133
15	assets	us-gaap:Assets	$577.7M	2024-12-31	2026-02-27	10-K	26-006133
16	current assets	us-gaap:AssetsCurrent	$630.8M	2025-12-31	2026-02-27	10-K	26-006133
17	current liabilities	us-gaap:LiabilitiesCurrent	$153.8M	2025-12-31	2026-02-27	10-K	26-006133
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.1B	2025-12-31	2026-02-27	10-K	26-006133
19	operating income	us-gaap:OperatingIncomeLoss	$123.3M	2025-12-31	2026-02-27	10-K	26-006133
20	book equity	us-gaap:StockholdersEquity	$648.0M	2025-12-31	2026-02-27	10-K	26-006133
21	liabilities	us-gaap:Liabilities	$415.2M	2025-12-31	2026-02-27	10-K	26-006133
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$211,000	2023-12-31	2026-02-27	10-K	26-006133
23	interest expense	us-gaap:InterestExpense	$12.6M	2023-12-31	2024-02-29	10-K	24-006144
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$329.0M	2024-12-31	2026-02-27	10-K	26-006133
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$233.7M	2023-12-31	2026-02-27	10-K	26-006133
26	revenue	us-gaap:Revenues	$2.8M	2022-12-31	2023-03-01	10-K	23-002610

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$214,000	2025-12-31	2026-02-27	10-K	26-006133
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$40.5M	2024-12-31	2026-02-27	10-K	26-006133
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$45,000	2024-12-31	2026-02-27	10-K	26-006133
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$31.4M	2023-12-31	2026-02-27	10-K	26-006133
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2023-12-31	2026-02-27	10-K	26-006133
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$176.2M	2022-12-31	2025-03-03	10-K	25-005908
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$14,000	2022-12-31	2025-03-03	10-K	25-005908
34	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$59,000	2025-12-31	2026-02-27	10-K	26-006133
35	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$107.4M	2025-12-31	2026-02-27	10-K	26-006133
36	income tax	us-gaap:IncomeTaxExpenseBenefit	-$339.8M	2025-12-31	2026-02-27	10-K	26-006133
37	current assets	us-gaap:AssetsCurrent	$566.4M	2024-12-31	2026-02-27	10-K	26-006133
38	current liabilities	us-gaap:LiabilitiesCurrent	$90.7M	2024-12-31	2026-02-27	10-K	26-006133
39	assets	us-gaap:Assets	$329.6M	2023-12-31	2025-03-03	10-K	25-005908
40	assets	us-gaap:Assets	$193.6M	2022-12-31	2024-02-29	10-K	24-006144
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	159,688,256	2026-02-25	2026-02-27	10-K	26-006133
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	157,070,575	2025-02-25	2025-03-03	10-K	25-005908

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.